DVT Prophylaxis in Hospitalized/Immobilized Patients
For acutely ill hospitalized medical patients at increased risk of thrombosis, use pharmacologic prophylaxis with LMWH, low-dose unfractionated heparin (5000 IU twice or three times daily), or fondaparinux 2.5 mg once daily 1.
Risk Stratification Determines Prophylaxis Need
High-risk patients requiring prophylaxis:
- Acute medical illness with immobilization
- Heart failure exacerbation
- Acute respiratory insufficiency
- Active infection/inflammatory disease
- Cancer patients with additional risk factors
- Critically ill ICU patients
Low-risk patients—do NOT give prophylaxis:
- Ambulatory medical patients
- Low thrombosis risk without immobilization
- Prophylaxis causes more harm than benefit in this group 1
Pharmacologic Options and Dosing
First-Line Agents (Equal Efficacy)
LMWH (preferred for convenience):
- Enoxaparin 40 mg SC daily
- Dalteparin 5000 IU SC daily
- Once-daily dosing improves compliance
Unfractionated Heparin:
- 5000 IU SC twice daily OR three times daily
- TID dosing shows trend toward better VTE prevention but significantly increased major bleeding risk (0.96 vs 0.35 per 1000 patient-days, p<0.001) 2
- Use BID dosing as standard; reserve TID for highest VTE risk patients
Fondaparinux:
Renal Impairment Adjustments
Severe renal dysfunction (CrCl <30 mL/min):
- Unfractionated heparin 5000 IU BID is safest choice—no renal clearance, no dose adjustment needed
- Dalteparin 5000 IU daily appears safe without bioaccumulation (no trough anti-Xa >0.40 IU/mL in critically ill patients with CrCl <30) 4
- However, dalteparin showed increased proximal DVT versus UFH in severe renal dysfunction (7.6% vs 3.7%, p=0.04) without bleeding difference 5
- Fondaparinux 1.5 mg daily (reduced dose) may be used but lacks robust RCT data 3
Dialysis-dependent ESRD:
- Either UFH 5000 IU BID or dalteparin 5000 IU daily acceptable
- No significant difference in VTE or bleeding between agents 5
Heparin Allergy Alternatives
For heparin-induced thrombocytopenia (HIT) or heparin allergy:
- Fondaparinux 2.5 mg SC daily—synthetic pentasaccharide with no heparin cross-reactivity
- This is the only pharmacologic option when all heparins are contraindicated
Contraindications and Special Situations
Active bleeding or high bleeding risk:
- Do NOT use pharmacologic prophylaxis 1
- Use mechanical prophylaxis instead:
- Graduated compression stockings (15-30 mmHg) OR
- Intermittent pneumatic compression
- Transition to pharmacologic prophylaxis when bleeding risk decreases 1
Critically ill patients:
- LMWH or LDUH recommended over no prophylaxis (Grade 2C) 1
- If bleeding/high bleeding risk: mechanical prophylaxis until safe to anticoagulate 1
Duration of Prophylaxis
Standard duration:
- Continue throughout hospitalization and immobilization period
- Stop at discharge or when patient mobilizes—do NOT extend beyond hospital stay 1
Exception—selected high-risk patients may benefit from extended prophylaxis:
- Women, age >75 years, severe ongoing immobility
- Insufficient evidence for routine extended prophylaxis; bleeding risk remains concern 3
Populations NOT Requiring Prophylaxis
- Chronically immobilized nursing home residents 1
- Ambulatory cancer patients without additional VTE risk factors 1
- Cancer patients with central venous catheters alone 1
Common Pitfalls
Avoid these errors:
- Giving prophylaxis to low-risk ambulatory patients (increases bleeding without benefit)
- Continuing prophylaxis after discharge in standard-risk patients
- Using full LMWH doses in severe renal impairment without considering UFH
- Forgetting fondaparinux as heparin alternative in HIT
- Using mechanical prophylaxis alone when pharmacologic prophylaxis is safe and indicated
Drug selection considerations:
- Patient preference and compliance matter
- Daily dosing (LMWH, fondaparinux) versus BID/TID (UFH)
- Hospital formulary costs
- Renal function dictates safety profile 1